Scribd Logo
Upload

Welcome to Scribd!

  • 3K views

    Usp 790

    Uploaded by

    jian_wyu
    Key points

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    Usp 790

    Uploaded by

    jian_wyu
    3K views1 page
    Key points

    Original Title

    USP 790

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Key points

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    3K views1 page

    Usp 790

    Uploaded by

    jian_wyu
    Key points

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    of 1

    Accessed from 10.6.1.

    1 by huahainf on Thu Mar 03 13:21:48 EST 2016


    Errata to First Supplement to USP 38NF 33

    Physical Tests / 790 Visible Particulates in Injections 1

    790 VISIBLE PARTICULATES IN INJECTIONS


    All products intended for parenteral administration must be visually inspected for the presence of particulate matter as specified in Injections 1. Dry solids, from which constituted solutions are prepared for injection, meet the requirements for Constituted Solutions in Injections 1 when they are prepared just prior to use. Where used in this chapter, the term essentially free
    means that when injectable drug products are inspected as described herein, no more than the specified number of units may
    be observed to contain visible particulates. Particulate matter is defined in Particulate Matter in Injections 788 as extraneous
    mobile undissolved particles, other than gas bubbles, unintentionally present in solutions. Examples of such particulate matter
    include, but are not limited to, fibers, glass, metal, elastomeric materials, and precipitates. However, some products, such as
    those derived from proteins, may contain inherent particles or agglomerates; in such cases, requirements for visible particulates are specified in the individual monograph or in the approved regulatory application.
    Where the nature of the contents or the containerclosure system permits only limited capability for inspection of the total
    contents, the 100% inspection of a batch shall be supplemented with the inspection of constituted (e.g., dried) or withdrawn
    (e.g., dark amber container, suspensions, highly-colored liquids) contents of a sample of containers from the batch. The destructive nature of these tests requires the use of a sample smaller1 than those traditionally used for non-destructive acceptance
    sampling after 100% inspection. While the tests described in this chapter may be useful during studies to examine product
    stability, this chapter is not intended to establish any new testing requirements for stability studies.

    Inspection Procedure
    Used along with 100% inspection during the manufacturing process, this procedure is sufficient to demonstrate that the
    batch is essentially free of visible particulates. A complete program for the control and monitoring of particulate matter remains an essential prerequisite.
    Inspected units must be free from visible particulates when examined without magnification (except for optical correction as
    may be required to establish normal vision) against a black background and against a white background. Illumination at the
    inspection point is maintained at a minimum intensity between 2000 and 3750 lux. This can be achieved through the use of
    two 13-W or 15-W fluorescent lamps (e.g., F13/T5 or F15/T8). The use of a high-frequency ballast to reduce flicker from the
    fluorescent lamps is recommended. Alternative light sources (e.g., incandescent, LED) that provide illumination at the point of
    inspection within the specified minimum intensity range are acceptable. Higher illumination intensity is recommended for examination of colored solutions or product in containers other than clear glass.
    Before performing the inspection, remove any adherent labels from the container, and wash and dry the outside. The unit
    under inspection should be gently swirled and/or inverted, ensuring that no air bubbles are produced, and inspected for approximately 5 s against each of the backgrounds. The presence of any particles should be recorded.

    Sampling at Batch Release (Following 100% Manufacturing Inspection)


    Sample and inspect the batch using ANSI/ASQ Z1.4 (or ISO 2859-1). General Inspection Level II, single sampling plans for
    normal inspection with an AQL of 0.65%. Alternative sampling plans with equivalent or better protection are acceptable. Not
    more than the specified number of units contains visible particulates.

    Product in Distribution2
    If it becomes necessary to evaluate product that has been shipped to customers (e.g., because of a complaint or regulatory
    concern), sample and inspect 20 units. If no particles are observed in the sample, the batch is considered essentially free of
    visible particulates. If available, additional units may be inspected to gain further information on the risk of particulates in the
    batch.
    1 The special level sampling plans described in ANSI/ASQ Z1.42008 or ISO 2859 are appropriate to guide the selection of sample size and acceptance criteria for
    this purpose.
    2 Testing outlined in Product in Distribution is permissible only if Sampling at Batch Release (Following 100% Manufacturing Inspection) has been successfully
    completed.

    Official from December 1, 2015


    Copyright (c) 2016 The United States Pharmacopeial Convention. All rights reserved.

    You might also like